These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 36456127)

  • 1. Phase I CAR-T Clinical Trials Review.
    Bulsara S; Wu M; Wang T
    Anticancer Res; 2022 Dec; 42(12):5673-5684. PubMed ID: 36456127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
    Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
    Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
    Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
    George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
    BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR T Cell Therapy in Pancreaticobiliary Cancers: a Focused Review of Clinical Data.
    Anwar MY; Williams GR; Paluri RK
    J Gastrointest Cancer; 2021 Mar; 52(1):1-10. PubMed ID: 32700185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial.
    Okumura S; Ishihara M; Kiyota N; Yakushijin K; Takada K; Kobayashi S; Ikeda H; Endo M; Kato K; Kitano S; Matsumine A; Nagata Y; Kageyama S; Shiraishi T; Yamada T; Horibe K; Takesako K; Miwa H; Watanabe T; Miyahara Y; Shiku H
    BMJ Open; 2022 Nov; 12(11):e065109. PubMed ID: 36375974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients.
    Zhang Y; Zhang Z; Ding Y; Fang Y; Wang P; Chu W; Jin Z; Yang X; Wang J; Lou J; Qian Q
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3725-3734. PubMed ID: 34032893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials.
    Shi D; Shi Y; Kaseb AO; Qi X; Zhang Y; Chi J; Lu Q; Gao H; Jiang H; Wang H; Yuan D; Ma H; Wang H; Li Z; Zhai B
    Clin Cancer Res; 2020 Aug; 26(15):3979-3989. PubMed ID: 32371538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bibliometric analysis of research trends and active research areas in chimeric antigen receptor T cell therapy for hematologic malignancies.
    Zhang G; Deng L; Lu H; Zhang W
    Int J Clin Pharm; 2024 Feb; 46(1):186-194. PubMed ID: 38087131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR-T Cell Therapy for Solid Tumors: Are we Still That Far? a Systematic Review of Literature.
    Karam A; Mjaess G; Martinez Chanza N; Aoun F; Bou Kheir G; Younes H; Kazzi H; Albisinni S; Roumeguère T
    Cancer Invest; 2022 Nov; 40(10):923-937. PubMed ID: 36102932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
    Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
    Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality Assessment of Pre-Clinical Studies of Chimeric Antigen Receptor T-Cell Therapy Products: A Point of Focus on Safety.
    Maharshi V; Diksha D; Gupta P
    Curr Drug Saf; 2022; 17(2):129-135. PubMed ID: 34323195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
    Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
    Front Immunol; 2021; 12():755866. PubMed ID: 34777368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol.
    Lalu MM; Kekre N; Montroy J; Ghiasi M; Hay K; McComb S; Weeratna R; Atkins H; Hutton B; Yahya A; Masurekar A; Sobh M; Fergusson DA
    Syst Rev; 2023 Jan; 12(1):9. PubMed ID: 36653879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor T cell therapy in oncology - Pipeline at a glance: Analysis of the ClinicalTrials.gov database.
    Moreno-Cortes E; Forero-Forero JV; Lengerke-Diaz PA; Castro JE
    Crit Rev Oncol Hematol; 2021 Mar; 159():103239. PubMed ID: 33497760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
    Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
    Front Immunol; 2022; 13():871661. PubMed ID: 35911706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-response correlation for CAR-T cells: a systematic review of clinical studies.
    Rotte A; Frigault MJ; Ansari A; Gliner B; Heery C; Shah B
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36549782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor T-cell therapies: Optimising the dose.
    Dasyam N; George P; Weinkove R
    Br J Clin Pharmacol; 2020 Sep; 86(9):1678-1689. PubMed ID: 32175617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trials.
    Raymakers AJN; Regier DA; Peacock SJ; Freeman CL
    J Cancer Policy; 2021 Dec; 30():100304. PubMed ID: 35559800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.